title: Pyoderma gangrenosum secondary to azacitidine in myelodysplastic syndrome.
authors.affiliation: Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
authors.forename: Eric
authors.initials: E
authors.lastname: Tseng
authors.forename: Raed
authors.initials: R
authors.lastname: Alhusayen
authors.forename: Shachar
authors.initials: S
authors.lastname: Sade
authors.forename: Rena
authors.initials: R
authors.lastname: Buckstein
authors.forename: Anca
authors.initials: A
authors.lastname: Prica
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D001374:Azacitidine / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000473:pathology; D017511:Pyoderma Gangrenosum / Q000139:chemically induced / Q000473:pathology
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine